Dietary Biomarkers 2.0: From Potential Towards Implementation.

Sponsor
Chalmers University of Technology (Other)
Overall Status
Recruiting
CT.gov ID
NCT05073523
Collaborator
(none)
24
Enrollment
1
Location
3
Arms
7.1
Anticipated Duration (Months)
3.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of this project is to fill a gap in the translation of dietary biomarkers as unbiased measures of food intake from high-end academic research into a methodology that ca be easily applied across academic, public and private health sector to objectively assess specific dietary intakes at group and individuals' level to a) improve understanding of diet and health relationships b) address compliance in dietary intervention studies and c) assess individuals' dietary intakes to guide their eating towards improved health. The study will be carried out as a three-way cross-over design with three different meal compositions (A, B, C) where each meal is provided 3 times per day during four days per meal. A wash-out period of 7 days where participants consume their habitual diet is implemented and a 3-day run-in before the study meal intervention. The first day of study meal intervention includes postprandial measurements during 8 hours.

Condition or DiseaseIntervention/TreatmentPhase
  • Other: Diet
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
Dietary Biomarkers 2.0: From Potential Towards Implementation. A Randomized Controlled Trial to Assess Dose-response Relationships for Dietary Biomarkers of Selected Foods
Actual Study Start Date :
Sep 27, 2021
Anticipated Primary Completion Date :
May 1, 2022
Anticipated Study Completion Date :
May 1, 2022

Arms and Interventions

ArmIntervention/Treatment
Other: Meal A

Diet: meal proportion 1

Other: Diet
All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.

Other: Meal B

Diet: meal proportion 2

Other: Diet
All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.

Other: Meal C

Diet: meal proportion 3

Other: Diet
All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.

Outcome Measures

Primary Outcome Measures

  1. Plasma concentrations of dietary candidate biomarkers (daidzein, genistein, hesperetin, naringenin, phloretin, kaempferol, 2-thiothiazolidine-4-carboxylic acid, sulforaphane) [24 hours]

    Difference in the plasma concentrations of diet specific biomarkers comparing before (baseline) and after intervention meal (average plasma concentration over the 24h period).

  2. Plasma concentrations of dietary biomarker candidates (proline betaine, 4-hydroxyphenylacetic acid, 4-hydroxyphenylpyruvate, indole-3-lactic acid, pipecolic acid, s-methylcysteine, avenacoside-A and avenacoside-B) [24 hours]

    Difference in the plasma concentrations of diet specific biomarkers comparing before (baseline) and after intervention meal (average plasma concentration over the 24 h period).

  3. Plasma concentration-time profile over 24h (AUCs) of dietary biomarker candidates ( daidzein, genistein, hesperetin, naringenin, phloretin, kaempferol, 2-thiothiazolidine-4-carboxylic acid, sulforaphane) [24 hours]

    Differences in plasma AUCs between the three intake levels for each biomarker candidate

  4. Plasma concentration-time profile over 24h (AUCs) of dietary biomarker candidates proline betaine, 4-hydroxyphenylacetic acid, 4-hydroxyphenylpyruvate, indole-3-lactic acid, pipecolic acid, s-methylcysteine, avenacoside-A and avenacoside-B [24 hours]

    Differences in plasma AUCs between the three intake levels.

Secondary Outcome Measures

  1. Gut microbiome [4 days]

    Fecal samples will analyzed for composition of the gut microbiome, baseline compared with after 4 days of intervention meals.

  2. Plasma metabolites [4 days]

    Untargeted metabolomics will be performed using established methods for plasma. Analyzed exploratorily using untargeted metabolomics to find potential biomarker panels that reflect the specific foods included in study meals. Baseline compared with after intervention meals.

  3. Urine metabolites [24 hours]

    Analyzed exploratorily using untargeted metabolomics to find potential biomarker panels that reflect the specific foods included in study meals.

  4. Fecal concentrations of diet specific biomarkers daidzein, genistein, hesperetin, naringenin, phloretin, kaempferol, 2-thiothiazolidine-4-carboxylic acid, sulforaphane [4 days]

    Evaluate new simple sampling techniques using faecal swabs.

  5. Fecal concentrations of diet specific biomarkers proline betaine, 4-hydroxyphenylacetic acid, 4-hydroxyphenylpyruvate, indole-3-lactic acid, pipecolic acid, s-methylcysteine, avenacoside-A and avenacoside-B) [4 days]

    Evaluate new simple sampling techniques using fecal swabs.

  6. Blood concentrations of diet specific biomarkers daidzein, genistein, hesperetin, naringenin, phloretin, kaempferol, 2-thiothiazolidine-4-carboxylic acid, sulforaphane [4 days]

    Evaluate new simple sampling techniques using dried blood spots.

  7. Blood concentrations of diet specific biomarkers proline betaine, 4-hydroxyphenylacetic acid, 4-hydroxyphenylpyruvate, indole-3-lactic acid, pipecolic acid, s-methylcysteine, avenacoside-A and avenacoside-B) [4 days]

    Evaluate new simple sampling techniques using dried blood spots.

  8. Urine concentrations of diet specific biomarkers daidzein, genistein, hesperetin, naringenin, phloretin, kaempferol, 2-thiothiazolidine-4-carboxylic acid, sulforaphane [4 days]

    Evaluate new simple sampling techniques using dried urine spots.

  9. Blood concentrations of diet specific biomarkers proline betaine, 4-hydroxyphenylacetic acid, 4-hydroxyphenylpyruvate, indole-3-lactic acid, pipecolic acid, s-methylcysteine, avenacoside-A and avenacoside-B [4 days]

    Evaluate new simple sampling techniques using dried urine spots.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Men and women

  • Age 18-80 years

  • Body mass index (BMI) 18.5-30 kg/m2

  • Fasting glucose ≤ 6.1 mmol/l

  • Low density lipoprotein (LDL), Cholesterol ≤ 5.30 mmol/L

  • Triglycerides ≤ 2.60 mmol/L

  • Signed informed consent

Exclusion Criteria:
  • Food allergies or intolerances preventing consumption of any products included in the study.

  • Strict vegetarian or vegan, participants must be able to eat dairy products as it is included in the study diet.

  • Unable to sufficiently understand written and spoken Swedish to provide written consent and understand information and instructions from the study personal.

  • Unable to satisfactorily complete the 3-day weighted food records.

  • Continuous/daily use of medication.

  • Pregnant, lactating or planning a pregnancy during the study period.

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1University of Gothenburg, Department of Food and Nutrition and Sport ScienceGothenburgSweden

Sponsors and Collaborators

  • Chalmers University of Technology

Investigators

  • Principal Investigator: Rikard Landberg, Dr, Chalmers University of Technology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rikard Landberg, Professor, Chalmers University of Technology
ClinicalTrials.gov Identifier:
NCT05073523
Other Study ID Numbers:
  • ChalmersUT
First Posted:
Oct 11, 2021
Last Update Posted:
Oct 11, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Oct 11, 2021